DOI: 10.1055/s-00000094

Zeitschrift für Gastroenterologie

References

Rowland A. et al.
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

Br J Cancer 2015;
112: 1888-1894

Download Bibliographical Data

Search in:
Access: